|
|
|
Volumn 44, Issue 18, 2014, Pages 26-
|
|
Why Sovaldi shouldn't cost $84,000.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 ((5 (2,4 DIOXO 3,4 DIHYDRO 2H PYRIMIDIN 1 YL) 4 FLUORO 3 HYDROXY 4 METHYLTETRAHYDROFURAN 2 YLMETHOXY)PHENOXYPHOSPHORYLAMINO)PROPIONIC ACID ISOPROPYL ESTER;
2-((5-(2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YLMETHOXY)PHENOXYPHOSPHORYLAMINO)PROPIONIC ACID ISOPROPYL ESTER;
DRUG DERIVATIVE;
URIDINE PHOSPHATE;
DRUG COST;
ECONOMICS;
EDITORIAL;
HEPATITIS C;
HUMAN;
UNITED STATES;
DRUG COSTS;
HEPATITIS C, CHRONIC;
HUMANS;
UNITED STATES;
URIDINE MONOPHOSPHATE;
|
|
EID: 84906319182
PISSN: 01607480
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (6)
|
|
References (0)
|
